Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice.

Oblak AL, Cope ZA, Quinney SK, Pandey RS, Biesdorf C, Masters AR, Onos KD, Haynes L, Keezer KJ, Meyer JA, Peters JS, Persohn SA, Bedwell AA, Eldridge K, Speedy R, Little G, Williams SP, Noarbe B, Obenaus A, Sasner M, Howell GR, Carter GW, Williams H, Lamb BT, Territo PR, Sukoff Rizzo SJ

Open source

DOI: 10.1002/trc2.12317
Published: 2022
Container: Alzheimer's & dementia (New York, N. Y.)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/trc2.12317,
  title = {Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice.},
  author = {Oblak AL and Cope ZA and Quinney SK and Pandey RS and Biesdorf C and Masters AR and Onos KD and Haynes L and Keezer KJ and Meyer JA and Peters JS and Persohn SA and Bedwell AA and Eldridge K and Speedy R and Little G and Williams SP and Noarbe B and Obenaus A and Sasner M and Howell GR and Carter GW and Williams H and Lamb BT and Territo PR and Sukoff Rizzo SJ},
  year = {2022},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  doi = {10.1002/trc2.12317},
  url = {https://doi.org/10.1002/trc2.12317}
}

RIS

TY  - JOUR
TI  - Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice.
AU  - Oblak AL
AU  - Cope ZA
AU  - Quinney SK
AU  - Pandey RS
AU  - Biesdorf C
AU  - Masters AR
AU  - Onos KD
AU  - Haynes L
AU  - Keezer KJ
AU  - Meyer JA
AU  - Peters JS
AU  - Persohn SA
AU  - Bedwell AA
AU  - Eldridge K
AU  - Speedy R
AU  - Little G
AU  - Williams SP
AU  - Noarbe B
AU  - Obenaus A
AU  - Sasner M
AU  - Howell GR
AU  - Carter GW
AU  - Williams H
AU  - Lamb BT
AU  - Territo PR
AU  - Sukoff Rizzo SJ
PY  - 2022
JO  - Alzheimer's & dementia (New York, N. Y.)
DO  - 10.1002/trc2.12317
UR  - https://doi.org/10.1002/trc2.12317
ER  -

APA

AL, O., ZA, C., SK, Q., RS, P., C, B., AR, M., KD, O., L, H., KJ, K., JA, M., JS, P., SA, P., AA, B., K, E., R, S., G, L., SP, W., B, N., A, O., M, S., GR, H., GW, C., H, W., BT, L., PR, T., & SJ, S. R. (2022). Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice.. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.12317

Source records

pubmed · retrieved 2026-09-26T17:27:44.667Z